Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Subclassification

被引:0
|
作者
Song, Byeong Geun [1 ]
Kim, Aryoung [1 ]
Goh, Myung Ji [1 ]
Kang, Wonseok [1 ]
Gwak, Geum-Youn [1 ]
Paik, Yong-Han [1 ]
Choi, Moon Seok [1 ]
Lee, Joon Hyeok [1 ]
Sinn, Dong Hyun [1 ]
机构
[1] Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Sch Med, Seoul, South Korea
关键词
Steatotic liver disease; Metabolic dysfunction-associated steatotic liver disease; Nonalcoholic fatty liver disease; Metabolic dysfunction-associated fatty liver disease; Hepatocellular carcinoma; CONSENSUS STATEMENT; METABOLIC SYNDROME; CANCER; NAFLD; MORTALITY; FIBROSIS; ALCOHOL; OBESITY; HCC;
D O I
10.1159/000538301
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Steatotic liver disease (SLD) is a new overarching term proposed to replace nonalcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease. Subclassification includes metabolic dysfunction-associated SLD (MASLD), MASLD with increased alcohol intake (MetALD), and cryptogenic SLD. This study aimed to investigate whether SLD and its subclassification could stratify hepatocellular carcinoma (HCC) risk. Methods: A cohort of 85,119 adults without viral hepatitis or heavy alcohol intake was analyzed for the risk of HCC according to SLD and its subclassification. The fibrosis-4 (FIB-4) index was used to estimate the degree of liver fibrosis. Results: During a median follow-up of 11.9 years, HCC was diagnosed in 123 individuals. The incidence rate of HCC per 1,000 person-years was higher in individuals with SLD than in those without SLD (0.197 vs. 0.071, p < 0.001), with an adjusted hazard ratio of 2.02 (95% confidence interval: 1.40-2.92). The HCC incidence rate per 1,000 person-years was 0, 0.180, and 0.648 for cryptogenic SLD, MASLD, and MetALD, respectively. When participants with SLD was further stratified by the FIB-4 index, the HCC incidence rate per 1,000 person-years was 0.074 for SLD with FIB-4 < 1.3 and 0.673 for SLD with FIB-4 >= 1.3. Of note, HCC risk was substantially high (HCC incidence rate: 1.847 per 1,000 person-years) for MetALD with FIB-4 >= 1.3. Conclusions: HCC risk was different by SLD and its subclassification. The utilization of SLD and its subclassification can aid in stratifying HCC risk and facilitate the identification of individuals requiring interventions to mitigate the risk of HCC.<br /> (c) 2024 The Author(s).Published by S. Karger AG, Basel
引用
收藏
页码:561 / 571
页数:11
相关论文
共 50 条
  • [1] LIVER STIFFNESS MEASUREMENT AND HEPATOCELLULAR CARCINOMA RISK IN METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE
    John, Binu
    Deng, Yangyang
    Singal, Amit
    Dahman, Bassam
    HEPATOLOGY, 2024, 80 : S768 - S769
  • [2] Metabolic-associated steatotic liver disease and hepatocellular carcinoma
    Catalano, Giovanni
    Chatzipanagiotou, Odysseas P.
    Kawashima, Jun
    Pawlik, Timothy M.
    EXPERT OPINION ON PHARMACOTHERAPY, 2024, 25 (17) : 2283 - 2291
  • [3] Risk factors for hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease
    Liew, Ian Yang
    Phua, Hwee Pin
    Lim, Wei Yen
    Chow, Angela
    Loo, Xiu Ying
    Sim, Kevin
    Lee, Eng Sing
    Yew, Kuo Chao
    JOURNAL OF HEPATOLOGY, 2024, 80 : S497 - S498
  • [4] Outcomes of radiofrequency ablation for hepatocellular carcinoma with concurrent steatotic liver disease
    Tsai, Feng-Pai
    Su, Tung-Hung
    Huang, Shang-Chin
    Tseng, Tai-Chung
    Hsu, Shih-Jer
    Liao, Sih-Han
    Hong, Chun-Ming
    Liu, Chen-Hua
    Yang, Hung-Chih
    Liu, Chun-Jen
    Chen, Pei-Jer
    Kao, Jia-Horng
    CANCER, 2025, 131 (01)
  • [5] Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Rodriguez, Luis A.
    Schmittdiel, Julie A.
    Liu, Liyan
    Macdonald, Brock A.
    Balasubramanian, Sreepriya
    Chai, Krisna P.
    Seo, Suk I.
    Mukhtar, Nizar
    Levin, Theodore R.
    Saxena, Varun
    JAMA NETWORK OPEN, 2024, 7 (07) : e2421019
  • [6] Hepatocellular carcinoma risk prediction and early detection in patients with metabolic dysfunction associated steatotic liver disease
    Liang, Jeff
    Kim, Naomy
    Yang, Ju Dong
    TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 9
  • [7] Steatotic liver disease and its newly proposed sub-classifications correlate with progression of the coronary artery calcium score
    Kim, Aryoung
    Kang, Danbee
    Choi, Sung Chul
    Cho, Juhee
    Sinn, Dong Hyun
    Gwak, Geum-Youn
    PLOS ONE, 2024, 19 (03): : 1 - 11
  • [8] The risk of hepatic decompensation in patients after the treatment for steatotic liver disease-related hepatocellular carcinoma
    Minami, Tatsuya
    Yamada, Tomoharu
    Fujishiro, Mitsuhiro
    Tateishi, Ryosuke
    JOURNAL OF HEPATOLOGY, 2024, 80 : S393 - S393
  • [9] Effects of dietary live microbes intake on a newly proposed classification system for steatotic liver disease
    Dai, Zhikun
    Bao, Zihong
    Lin, Hanyuan
    Yang, Qinglong
    Huang, Jingtao
    Zhang, Xuan
    Luo, Nan
    Tang, Haoxian
    Zhou, Xiaohui
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [10] Impact of clonal hematopoiesis of indeterminate potential on hepatocellular carcinoma in steatotic liver disease
    Pelusi, Serena
    Marchetti, Alfredo
    Malvestiti, Francesco
    Ricchiuti, Antony
    Ronzoni, Luisa
    Lionetti, Marta
    Moretti, Vittoria
    Bugianesi, Elisabetta
    Miele, Luca
    Gentilucci, Umberto Vespasiani
    Dongiovanni, Paola
    Federico, Alessandro
    Soardo, Giorgio
    D'Ambrosio, Roberta
    Reeves, Helen Louise
    La Mura, Vincenzo
    Prati, Daniele
    Bolli, Niccolo
    Valenti, Luca
    JOURNAL OF HEPATOLOGY, 2024, 80 : S459 - S459